Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
Panu WetwittayakhlangFarah AlbaderPetra A GolovicsGustavo Drügg HahnTalat BessissowAlain BittonWaqqas AfifGary WildPeter Laszlo LakatosPublished in: Canadian journal of gastroenterology & hepatology (2021)
The prevalence of COVID-19 infection among patients with IBD was lower than that in the general population in Canada. Severe COVID-19, mortality, and flare of IBD were relatively rare, while a large proportion of patients received COVID-19 vaccination. Older age, comorbidities, active IBD disease, and systemic corticosteroid, but not immunosuppressive or biological therapy, were associated with severe COVID-19 infection.
Keyphrases
- coronavirus disease
- sars cov
- patients with inflammatory bowel disease
- newly diagnosed
- risk factors
- ejection fraction
- early onset
- respiratory syndrome coronavirus
- ulcerative colitis
- physical activity
- prognostic factors
- stem cells
- type diabetes
- coronary artery disease
- mesenchymal stem cells
- patient reported outcomes
- bone marrow